Keywords: MRSA, Theravance, Astellas, J&J, Basilea, AstraZeneca, Takeda, Market

Emerging compounds will drive modest growth in the MRSA drug market through 2018, says Decision Resources

Article | 24 November 2009

Print This

Over the next decade, modest growth in the methicillin-resistant Staphylococcus aureus (MRSA) drug market will be driven in part by ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in